NasdaqGM:MNKDBiotechs
The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update
MannKind Corporation recently received FDA approval for an update to Afrezza’s Prescribing Information, refining recommended starting mealtime doses when adults switch from injected or pump-based insulin to the inhaled therapy, based on new modeling and clinical data.
This label change is significant because clearer conversion guidance may influence how comfortably physicians transition suitable diabetes patients to Afrezza’s ultra rapid-acting inhaled insulin option, while keeping its known...